Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 35

1.

Correlation between oritavancin and vancomycin minimum inhibitory concentrations in staphylococci.

Arhin FF, Draghi DC, Pillar CM, Moeck G, Sahm DF.

Int J Antimicrob Agents. 2012 Dec;40(6):562-3. doi: 10.1016/j.ijantimicag.2012.06.019. Epub 2012 Aug 4. No abstract available.

PMID:
22871370
2.

Longitudinal analysis of the in vitro activity profile of oritavancin and comparator glycopeptides against Gram-positive organisms from Europe: 2005-2008.

Arhin FF, Moeck G, Draghi DC, Pillar CM, Sahm DF.

Int J Antimicrob Agents. 2010 Nov;36(5):474-6. doi: 10.1016/j.ijantimicag.2010.07.010. Epub 2010 Sep 16. No abstract available.

PMID:
20846829
3.

Comparative in vitro activity profile of oritavancin against recent gram-positive clinical isolates.

Arhin FF, Draghi DC, Pillar CM, Parr TR Jr, Moeck G, Sahm DF.

Antimicrob Agents Chemother. 2009 Nov;53(11):4762-71. doi: 10.1128/AAC.00952-09. Epub 2009 Sep 8.

4.

Antimicrobial activity among multidrug-resistant Streptococcus pneumoniae isolated in the United States, 2001-2005.

Thornsberry C, Brown NP, Draghi DC, Evangelista AT, Yee YC, Sahm DF.

Postgrad Med. 2008 Sep;120(3 Suppl 1):32-8. doi: 10.3810/pgm.2008.09.suppl52.282.

PMID:
18931469
5.

Tracking resistance among bacterial respiratory tract pathogens: summary of findings of the TRUST Surveillance Initiative, 2001-2005.

Sahm DF, Brown NP, Draghi DC, Evangelista AT, Yee YC, Thornsberry C.

Postgrad Med. 2008 Sep;120(3 Suppl 1):8-15. doi: 10.3810/pgm.2008.09.suppl52.279.

PMID:
18931466
6.

Newly defined in vitro quality control ranges for oritavancin broth microdilution testing and impact of variation in testing parameters.

Arhin FF, Tomfohrde K, Draghi DC, Aranza M, Parr TR Jr, Sahm DF, Moeck G.

Diagn Microbiol Infect Dis. 2008 Sep;62(1):92-5. doi: 10.1016/j.diagmicrobio.2008.05.009. Epub 2008 Jul 9.

PMID:
18614315
7.

In vitro activity of tigecycline against gram-positive and gram-negative pathogens as evaluated by broth microdilution and Etest.

Pillar CM, Draghi DC, Dowzicky MJ, Sahm DF.

J Clin Microbiol. 2008 Sep;46(9):2862-7. doi: 10.1128/JCM.00637-08. Epub 2008 Jul 2.

8.

Increasing prevalence of methicillin resistance in serious ocular infections caused by Staphylococcus aureus in the United States: 2000 to 2005.

Asbell PA, Sahm DF, Shaw M, Draghi DC, Brown NP.

J Cataract Refract Surg. 2008 May;34(5):814-8. doi: 10.1016/j.jcrs.2008.01.016.

PMID:
18471638
9.

Comparative surveillance study of telavancin activity against recently collected gram-positive clinical isolates from across the United States.

Draghi DC, Benton BM, Krause KM, Thornsberry C, Pillar C, Sahm DF.

Antimicrob Agents Chemother. 2008 Jul;52(7):2383-8. doi: 10.1128/AAC.01641-07. Epub 2008 Apr 28.

10.

In vitro activity of telavancin against recent Gram-positive clinical isolates: results of the 2004-05 Prospective European Surveillance Initiative.

Draghi DC, Benton BM, Krause KM, Thornsberry C, Pillar C, Sahm DF.

J Antimicrob Chemother. 2008 Jul;62(1):116-21. doi: 10.1093/jac/dkn124. Epub 2008 Apr 19.

PMID:
18424792
11.

Susceptibility of Staphylococcus aureus isolated from skin and wound infections in the United States 2005-07: laboratory-based surveillance study.

Tillotson GS, Draghi DC, Sahm DF, Tomfohrde KM, Del Fabro T, Critchley IA.

J Antimicrob Chemother. 2008 Jul;62(1):109-15. doi: 10.1093/jac/dkn149. Epub 2008 Apr 8.

PMID:
18397923
12.

Baseline in vitro activity of tigecycline among key bacterial pathogens exhibiting multidrug resistance.

Draghi DC, Tench S, Dowzicky MJ, Sahm DF.

Chemotherapy. 2008;54(2):91-100. doi: 10.1159/000118660. Epub 2008 Feb 25.

PMID:
18303257
13.

Effect of polysorbate 80 on oritavancin binding to plastic surfaces: implications for susceptibility testing.

Arhin FF, Sarmiento I, Belley A, McKay GA, Draghi DC, Grover P, Sahm DF, Parr TR Jr, Moeck G.

Antimicrob Agents Chemother. 2008 May;52(5):1597-603. doi: 10.1128/AAC.01513-07. Epub 2008 Feb 25.

14.
15.

Bactericidal activity and resistance development profiling of dalbavancin.

Goldstein BP, Draghi DC, Sheehan DJ, Hogan P, Sahm DF.

Antimicrob Agents Chemother. 2007 Apr;51(4):1150-4. Epub 2007 Jan 12.

16.

Geographically-based evaluation of multidrug resistance trends among Streptococcus pneumoniae in the USA: findings of the FAST surveillance initiative (2003-2004).

Draghi DC, Jones ME, Sahm DF, Tillotson GS.

Int J Antimicrob Agents. 2006 Dec;28(6):525-31. Epub 2006 Nov 13.

PMID:
17101260
17.

Current antimicrobial resistance profiles among methicillin-resistant Staphylococcus aureus encountered in the outpatient setting.

Draghi DC, Sheehan DF, Hogan P, Sahm DF.

Diagn Microbiol Infect Dis. 2006 Jun;55(2):129-33. Epub 2006 Mar 20.

PMID:
16542812
18.
19.

Emerging resistance among bacterial pathogens in the intensive care unit--a European and North American Surveillance study (2000-2002).

Jones ME, Draghi DC, Thornsberry C, Karlowsky JA, Sahm DF, Wenzel RP.

Ann Clin Microbiol Antimicrob. 2004 Jul 29;3:14.

20.

Antibiotic susceptibility of bacteria most commonly isolated from bone related infections: the role of cephalosporins in antimicrobial therapy.

Jones ME, Karlowsky JA, Draghi DC, Thornsberry C, Sahm DF, Nathwani D.

Int J Antimicrob Agents. 2004 Mar;23(3):240-6.

PMID:
15164964
21.

Rates of antimicrobial resistance among common bacterial pathogens causing respiratory, blood, urine, and skin and soft tissue infections in pediatric patients.

Jones ME, Karlowsky JA, Draghi DC, Thornsberry C, Sahm DF, Bradley JS.

Eur J Clin Microbiol Infect Dis. 2004 Jun;23(6):445-55. Epub 2004 May 20.

PMID:
15156358
22.

Prevalence and antimicrobial susceptibilities of bacteria isolated from blood cultures of hospitalized patients in the United States in 2002.

Karlowsky JA, Jones ME, Draghi DC, Thornsberry C, Sahm DF, Volturo GA.

Ann Clin Microbiol Antimicrob. 2004 May 10;3:7.

23.
25.

Antibiotic susceptibility of isolates of Bacillus anthracis, a bacterial pathogen with the potential to be used in biowarfare.

Jones ME, Goguen J, Critchley IA, Draghi DC, Karlowsky JA, Sahm DF, Porschen R, Patra G, DelVecchio VG.

Clin Microbiol Infect. 2003 Sep;9(9):984-6.

26.

Epidemiology and antibiotic susceptibility of bacteria causing skin and soft tissue infections in the USA and Europe: a guide to appropriate antimicrobial therapy.

Jones ME, Karlowsky JA, Draghi DC, Thornsberry C, Sahm DF, Nathwani D.

Int J Antimicrob Agents. 2003 Oct;22(4):406-19.

PMID:
14522104
27.

Clinical isolates of Streptococcus pneumoniae with different susceptibilities to ceftriaxone and cefotaxime.

Karlowsky JA, Jones ME, Draghi DC, Sahm DF.

Antimicrob Agents Chemother. 2003 Oct;47(10):3155-60.

29.
30.

Activity of daptomycin against susceptible and multidrug-resistant Gram-positive pathogens collected in the SECURE study (Europe) during 2000-2001.

Critchley IA, Draghi DC, Sahm DF, Thornsberry C, Jones ME, Karlowsky JA.

J Antimicrob Chemother. 2003 Mar;51(3):639-49.

PMID:
12615866
31.

Antimicrobial susceptibilities of Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis isolated in two successive respiratory seasons in the US.

Karlowsky JA, Draghi DC, Thornsberry C, Jones ME, Critchley IA, Sahm DF.

Int J Antimicrob Agents. 2002 Aug;20(2):76-85.

PMID:
12297355
32.

In vitro susceptibility of recent clinical isolates of pneumococci to the investigational cephalosporin cefditoren.

Karlowsky JA, Jones ME, Draghi DC, Critchley IA, Thornsberry C, Sahm DF.

Diagn Microbiol Infect Dis. 2002 Jan;42(1):59-64.

PMID:
11821173
33.

Activity of cefditoren against beta-lactamase-positive and -negative Haemophilus influenzae and Moraxella catarrhalis.

Karlowsky JA, Critchley IA, Draghi DC, Jones ME, Thornsberry C, Sahm DF.

Diagn Microbiol Infect Dis. 2002 Jan;42(1):53-8.

PMID:
11821172
34.

Activities of faropenem, an oral beta-lactam, against recent U.S. isolates of Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis.

Critchley IA, Karlowsky JA, Draghi DC, Jones ME, Thornsberry C, Murfitt K, Sahm DF.

Antimicrob Agents Chemother. 2002 Feb;46(2):550-5.

35.

Comparative activity of cefditoren and other oral beta-lactams against nonpneumococcal streptococci.

Thornsberry C, Karlowsky JA, Kelly LJ, Draghi DC, Critchley IA, Jones ME, Sahm DF.

Chemotherapy. 2001 Sep-Oct;47(5):332-43.

PMID:
11561135

Supplemental Content

Loading ...
Support Center